e-SPACE Cardio-Renal-Metabolic 2023

Published: 25 March 2023

Views:
12586
Likes:
7

Views:
12586
Likes:
7
Share:

Now Playing
Part 2 | Session 2 of 9
Satellite symposium – Management of CKD without diabetes – SGLT2 inhibitors, the new standard of care (Supported by an educational grant from AstraZeneca)
Michel Jadoul, David Wheeler, Pinar Topsever

Up Next
1h 10s

Part 2 | Session 3 Plenary session 8 – Diabetes and cardio-renal disease: the relevance of early treatment with the right drug
Peter Rossing, Antonio Ceriello, Francesco Prattichizzo, Apostolos G Tsapas, Melanie Davies, John JV McMurray
31m 5s

Part 2 | Session 4 Meet the expert – Management of hyperkalemia in cardiorenal disease ‒ practical guidance and novel therapeutic options (Supported by an unrestricted educational grant by CSL Vifor)
Gianluigi Savarese, Jolanta Małyszko
59m 17s

Part 2 | Session 5 Plenary session 9 – Managing “metals”
Javed Butler, Shelley Zieroth, Iain Macdougall, John GF Cleland, Matthew R Weir, Paola Fioretto
41m 30s

Part 2 | Session 6 Satellite symposium – Management of hyperkalemia across the cardiorenal spectrum (Supported by an educational grant from AstraZeneca)
Matthew R Weir, Andrew JS Coats, Shelley Zieroth, Kieran McCafferty
1h 2m 16s

Part 2 | Session 7 Plenary session 10 – Management of diabetes with kidney disease
Peter Rossing, Sankar Navaneethan, Maria Luiza Caramori, Ian de Boer, Erin D Michos
1h 3m 10s

Part 2 | Session 8 Plenary session 11 – Managing frail and elderly patients
Fausto J Pinto, Mitja Lainscak, A Enrique Caballero, Cynthia Delgado, Ambarish Pandey
1h 1m 47s

Part 2 | Session 9 Plenary session 12 – Managing end-stage disease: focus on QoL
Kerri L Cavanaugh, Fausto J Pinto, John Spertus, Giuseppe Paolisso, Manjula Kurella Tamura, Suzanne Arnold

58m 8s

Part 1 | Session 1 Plenary session 1 – HFpEF Andrew JS Coats, Giuseppe Rosano, Eberhard Standl, María José Soler, Stefan Anker

51m 57s

Part 1 | Session 2 Satellite symposium – SGLT2 inhibitors in cardio-renal-metabolic patients – the perfect fit? (Supported by an educational grant from the Boehringer Ingelheim & Lilly Alliance) Stefan Anker, Paola Fioretto, Michel Jadoul

56m 38s

Part 1 | Session 3 Plenary session 2 – SGLT2 updates Andrew JS Coats, Hiddo Lambers Heerspink, Antonio Ceriello, Gianluigi Savarese, Christoph Wanner

31m 38s

Part 1 | Session 4 Meet the expert – Management of heart failure in real world clinical practice – insights from the REWOLUTION HF surveys Ewa Jankowska, Andrew JS Coats

58m 54s

Part 1 | Session 5 Plenary session 3 – Weight management in CRM disease Luc Van Gaal, Wolfram Doehner, Milton Packer, Carel le Roux, Tammy Lyn Kindel, Ildiko Lingvay

30m 11s

Part 1 | Session 6 Meet the expert – Implementation patterns and challenges in HF care: insights from the EVOLUTION HF study (Supported by an educational grant from AstraZeneca) Orly Vardeny, Gianluigi Savarese

1h 6m 3s

Part 1 | Session 7 Plenary session 4 – Guidelines implementation for acutely ill patients Stephan Von Haehling, Mehriban Isgandar, Alexandre Mebazaa, Adriaan A Voors, Marat Fudim, Vijay Chopra

58m 41s

Part 1 | Session 8 Plenary session 5 – Mineralocorticoids antagonists in CRM disease Javed Butler, Sunil Bhandari, Edgar V Lerma, Faiez Zannad, Janani Rangaswami, Gerasimos Filippatos

25m 15s

Part 1 | Session 9 Meet the expert – Single pill combination (SPC) in Cardiorenal metabolic (CRM) disease Stefan Anker, Muthiah Vaduganathan

59m 5s

Part 1 | Session 10 Plenary session 6 – Diuretics: old drugs, new data, new approaches Nisha Bansal, Christopher Wilcox, Wilfried Mullens, Areef Ishani, William T Abraham

1h 20s

Part 2 | Session 1 Plenary session 7 – CRM drug management in patients with low eGFR and type 2 diabetes John J Atherton, Petar M Seferovic, John GF Cleland, Michael Böhm, Meg Jardine, Daniël van Raalte

Average (ratings)

No ratings

Your rating

Overview

e-SPACE Cardio-Renal-Metabolic 2023 was the third edition of the annual global online conference that explores how leading experts, in cardiology, nephrology, and diabetology, are treating the interrelated diseases.

Course leadership Prof Stefan Anker (Berlin, DE), Dr Javed Butler (Texas, US), Prof Antonio Ceriello (Milan, IT), Prof Tara I Chang (California, US), Prof Ian de Boer (Washington, US), Prof Peter Rossing (Copenhagen, DK) and Prof Shelley Zieroth (Winnipeg, CA) lead an interactive programme of plenary sessions, meet the expert, case discussions and satellite symposium sessions focusing on the patient journey.

For the first time, e-SPACE Cardio-Renal-Metabolic 2023 brought together TMA’s mandate for the delivery of continuing professional development to healthcare professionals to achieve concordance with appropriate treatment plans, alongside KDIGO's mission to improve the care and outcomes of patients with kidney disease worldwide through the development and implementation of global clinical practice guidelines, with Radcliffe Cardiology’s goal to deliver cardiovascular knowledge to best support cardiovascular communities transform theory into practice.

e-SPACE Cardio-Renal-Metabolic 2023 would like to thank the following sponsors:

Learning Objectives

Review the burden of diabetes, kidney disease and heart failure including morbidity, excess mortality, and reduced quality of life affecting individuals around the world
Describe the complexity and interlink between the three conditions
Discuss existing guidelines and best approaches for screening patients
Review evidence-based management strategies for diabetes, cardiovascular disease, heart failure, kidney disease & obesity including SLGT2i, GLP-1RA, new non-steroidal mineralocorticoid receptor antagonists and other emerging therapies
Foster cross-collaboration between other cardiorenal / metabolic specialists and primary care physicians and allied health care professionals in order to improve patients outcomes

Target Audience

Cardiologists
Nephrologists
Diabetologists
General Practitioners (GPs)
HF Specialists
Nurses, Pharmacists, and other Allied Healthcare Professionals

More from this programme

Part 1

Day One

10 sessions
Plenary session 1 – HFpEF	Watch now
Satellite symposium – SGLT2 inhibitors in cardio-renal-metabolic patients – the perfect fit? (Supported by an educational grant from the Boehringer Ingelheim & Lilly Alliance)	Watch now
Plenary session 2 – SGLT2 updates	Watch now
Meet the expert – Management of heart failure in real world clinical practice – insights from the REWOLUTION HF surveys	Watch now
Plenary session 3 – Weight management in CRM disease	Watch now
Meet the expert – Implementation patterns and challenges in HF care: insights from the EVOLUTION HF study (Supported by an educational grant from AstraZeneca)	Watch now
Plenary session 4 – Guidelines implementation for acutely ill patients	Watch now
Plenary session 5 – Mineralocorticoids antagonists in CRM disease	Watch now
Meet the expert – Single pill combination (SPC) in Cardiorenal metabolic (CRM) disease	Watch now
Plenary session 6 – Diuretics: old drugs, new data, new approaches	Watch now

Part 2

Day Two

9 sessions
Plenary session 7 – CRM drug management in patients with low eGFR and type 2 diabetes	Watch now
Satellite symposium – Management of CKD without diabetes – SGLT2 inhibitors, the new standard of care (Supported by an educational grant from AstraZeneca)	Watch now
Plenary session 8 – Diabetes and cardio-renal disease: the relevance of early treatment with the right drug	Watch now
Meet the expert – Management of hyperkalemia in cardiorenal disease ‒ practical guidance and novel therapeutic options (Supported by an unrestricted educational grant by CSL Vifor)	Watch now
Plenary session 9 – Managing “metals”	Watch now
Satellite symposium – Management of hyperkalemia across the cardiorenal spectrum (Supported by an educational grant from AstraZeneca)	Watch now
Plenary session 10 – Management of diabetes with kidney disease	Watch now
Plenary session 11 – Managing frail and elderly patients	Watch now
Plenary session 12 – Managing end-stage disease: focus on QoL	Watch now

Faculty Biographies

Michel Jadoul

Clinical Professor

Prof Michel Jadoul is a Clinical Professor at Université catholique de Louvain, Ottignies-Louvain-la-Neuve, BE.

Prof Jadoul's clinical activities include the follow-up of hemodialysis and CKD patients. His main research interests include hepatitis C, beta2m amyloidosis and other complications in hemodialysis patients, as well as CV complications after kidney TP and various causes of kidney disease (especially drugs).

He has (co)-authored over 330 scientific papers, most of them published in major nephrology journals.

View full profile

David Wheeler

David Wheeler is Professor of Kidney Medicine at University College London and Honorary Consultant Nephrologist at the Royal Free London NHS Foundation Trust.Professor Wheeler is a clinician scientist interested in the complications of chronic kidney disease (CKD), specifically those that increase the burden of cardiovascular disease and/or accelerate progression of kidney failure. He has participated in the development and running of several large-scale clinical trials testing lipid-lowering regimens, calcimimetics, intravenous iron, sodium–glucose co-transporter 2 inhibitors and hypoxia-inducible factor stabilisers in patients with CKD.Professor Wheeler has also been involved in the development of clinical practice guidelines for several organisations, most recently for Kidney Disease: Improving Global Outcomes (KDIGO). He served as KDIGO co-Chair between 2012 and 2019. His ongoing roles include serving as the National Specialty Lead for the National Institute of Health Research…

View full profile

Pinar Topsever

Department of Family Medicine

Prof Pinar Topsever works in the Department of Family Medicine at Acıbadem University School of Medicine, Istanbul, TR.

View full profile

Comments

You must be to comment. If you are not registered, you can register here.